Dry powder formulations are often composed of fine drug particles and coarser carrier particles, typically alpha-lactose monohydrate. However, the performance of a powder formulation may be highly dependent on the lactose quality and source. This study investigated the characteristics of lactose that influence the drug-to-carrier interaction and the performance of lactose-based dry powder inhaler formulations. The selected lactoses differed in the preparation processes and the content of fine lactose particles. Efficiency testing was done using fluticasone propionate and terbutaline sulphate as model drugs. Inverse gas chromatography was used to determine the surface heterogeneity distribution of different energy sites of the lactose and to understand the mechanism by which the fine carrier particles can improve the performance of dry powder inhalers. To assess the adhesion of respirable-sized drug to carrier particles, a simple method was developed based on aspiration and considering the whole blend as it is used in dry powder inhalers. When the percentage of fine lactose is high, a lower quantity of drug adheres to the lactose and/or the adhesion force is also lower. This was confirmed by the aerosolization assays done in the TSI (twin stage impinger). A correlation was observed between adhesion characteristics and inertial impaction. For both drugs, the fine particle fractions were highest in blends that present a greater proportion of lactose fine particles. A fairly good correlation between the fine particle fractions of both drugs and the peak max value and the AUC (area under curve) were found by inverse gas chromatography. With higher fine particle fraction values, which correspond to higher content of fines, the peak maxima determined by inverse gas chromatography were shifted to higher adsorption potentials, which supports the agglomeration hypothesis. (C) 2011 Elsevier B.V. All rights reserved.
机构:
Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA USAUniv Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA USA
Tashkin, Donald P.
Koltun, Arkady
论文数: 0引用数: 0
h-index: 0
机构:
Mylan Inc, Global Med Affairs, Canonsburg, PA USAUniv Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA USA
Koltun, Arkady
Wallace, Roisin
论文数: 0引用数: 0
h-index: 0
机构:
Mylan Inc, Global Device Dev, Dublin, IrelandUniv Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA USA
机构:
Univ N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC 27599 USAUniv N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC 27599 USA
Xu, Zhen
Mansour, Heidi M.
论文数: 0引用数: 0
h-index: 0
机构:
Univ N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC 27599 USAUniv N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC 27599 USA
Mansour, Heidi M.
Mulder, Tako
论文数: 0引用数: 0
h-index: 0
机构:
DMV Fonterra Excipients, Goch, Nordrhein Westf, GermanyUniv N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC 27599 USA
Mulder, Tako
McLean, Richard
论文数: 0引用数: 0
h-index: 0
机构:
Pfizer Inc, Sandwich, Kent, EnglandUniv N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC 27599 USA
McLean, Richard
Langridge, John
论文数: 0引用数: 0
h-index: 0
机构:
DMV Fonterra Excipients, Goch, Nordrhein Westf, GermanyUniv N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC 27599 USA
Langridge, John
Hickey, Anthony J.
论文数: 0引用数: 0
h-index: 0
机构:
Univ N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC 27599 USAUniv N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC 27599 USA